Clinical Trial Search

Primary: At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale) — 15; 14 participants

Primary: Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT) — 170; 33 participants

Primary: Change From Baseline in the Apathy Evaluation Scale - Clinician Rated Version (AES-C) Total Score at Week 8 — -13.88; -13.50 units on a scale — p=0.612

Primary: Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3 — 10; 18; 14 participants

Primary: Pain — 3.72; 5.41 scores on a scale

Primary: Number of Subjects With Low Disease Activity (DAS28 Less Than 3.2) and No Radiographic Progression From Baseline (Change in mTSS Less Than or Equal to 0.5) at Week 78…

Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001

Primary: Percentage of Participants With Major Adverse Cardiac Events (MACE) (Incidence of MACE) at 30 Days Post-percutaneous Coronary Intervention (PCI) — 14.7; 15.7; 0.6; 0.6…

Primary: Change in HbA1c From Baseline — -0.48; -0.74 percentage point change

Primary: Percent of Patients Initiating Vivitrol Treatment Who Receive 3 Consecutive Monthly Vivitrol Injections — 40 Percent of participants

Primary: Weaning Time — 4.95; 10.15; 4.95; 10.15 day

Primary: Patient Preference in Terms of Overall Preference and Preference of Taste, Consistency, and Portability. — 7; 6; 12; 11 participants

Primary: Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels — 1027.4; 1014.7 Picograms per milliliter (pg/ml)

Primary: 90% Constant Work Rate (CWR) Treadmill Endurance Time at 96 Weeks - Double-Blind Phase — 297.1; 336.6 seconds — p=0.1062

Primary: Intraocular Pressure (IOP) at Week 12 — 17.75; 17.90 Millimeters of mercury (mm Hg)